<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163520">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969436</url>
  </required_header>
  <id_info>
    <org_study_id>109995</org_study_id>
    <nct_id>NCT00969436</nct_id>
  </id_info>
  <brief_title>Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM</brief_title>
  <official_title>A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess non-inferiority of two different vaccination regimens
      using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months)
      and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™
      administered at 9 months of age followed by concomitant administration of Priorix™ with
      Varilrix™ at 15 months of age in a measles endemic environment such as India.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates for measles, mumps, rubella and varicella</measure>
    <time_frame>Approximately 42 to 56 days after the second vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rates for measles, mumps and rubella</measure>
    <time_frame>Approximately 42 to 56 days after the first vaccine dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measles, mumps, rubella and varicella antibody titres</measure>
    <time_frame>42 to 56 days after the first and second dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local symptoms</measure>
    <time_frame>Within 4 days (Day 0 - 3) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited general symptoms</measure>
    <time_frame>Within 43 days (Day 0 - 42) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited signs and symptoms</measure>
    <time_frame>Within 43 days (Day 0 - 42) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>From Day 0 up to 42 to 56 days after the second dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Varicella</condition>
  <condition>Rubella</condition>
  <condition>Mumps</condition>
  <condition>Measles</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive GSK Biologicals' MMRV 208136 vaccine at 9 and 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Priorix™ at 9 months and GSK Biologicals' MMRV 208136 vaccine at 15 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group will receive Priorix™ at 9 months and Priorix™ + Varilrix™ at 15 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biological's investigational MMRV vaccine 208136</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Priorix™</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varilrix™</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  Male or female subjects between and including 9 and 10 months of age at the time of
             the first vaccination.

          -  Written informed consent obtained from the the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             starting 30 days prior to administration of any dose of the study vaccine, up to 42
             days after the vaccine dose with the exception of hepatitis A vaccine and oral
             poliovirus vaccine .

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-registered product.

          -  Previous vaccination against measles, mumps, rubella and varicella.

          -  History of measles, mumps, rubella and/or varicella diseases.

          -  Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to
             the start of the study.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines including neomycin.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Axillary temperature &gt; 37.5°C (99.5°F) / Rectal temperature &gt; 38°C (100.4°F).

          -  Administration of immunoglobulins and/or any blood products during the six months
             before entering the study or planned administration during the study period.

          -  Presence of a susceptible high-risk person in the same household during the study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>10 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goa</city>
        <zip>403202</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolkata</city>
        <zip>700073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>August 20, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>April 1, 2011</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mumps</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccines</keyword>
  <keyword>Safety</keyword>
  <keyword>Rubella</keyword>
  <keyword>Combined Vaccine</keyword>
  <keyword>Varicella Vaccine</keyword>
  <keyword>Children</keyword>
  <keyword>Measles</keyword>
  <keyword>Humans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Rubella</mesh_term>
    <mesh_term>Mumps</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109995</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
